GRTX: Galera Therapeutics, Inc. Stock

by  •  • Comments Off on GRTX: Galera Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.47
Enterprise Value ($M) 154.60
Book Value ($M) -143.67
Book Value / Share -1.90
Price / Book -0.05
NCAV ($M) -143.77
NCAV / Share -1.91
Price / NCAV -0.05

Profitability (mra)
Return on Invested Capital (ROIC) -2.57
Return on Assets (ROA) -0.96
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 6.00
Current Ratio 6.00

Balance Sheet (mrq) ($M)
Current Assets 10.00
Assets 10.10
Liabilities 153.77
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -14.15
Net Income -18.96

Cash Flow Statement (mra) ($M)
Cash From Operations -12.14
Cash from Investing -0.05
Cash from Financing 2.22

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Ikarian Capital, LLC 9.99
05-16 13G Soffer Rochel 10.90
05-16 13G/A Schneid Yair 19.90 0.00
2024-04-16 13G ALPHA PHARMA Investments LLC 5.06

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-12-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REP
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)

Similar Companies
GNMSF – Genmab A/S GNTLF – Genetic Technologies Limited
GPLB – Green Planet Bioengineering Co., Ltd. GSAC – GelStat Corp.
GSGTF – GenSight Biologics S.A.


Financial data and stock pages provided by
Fintel.io